Critical Summary This article evaluates the cost-effectiveness of recently available respiratory syncytial virus (RSV) immunization options—nirsevimab (a long-acting monoclonal antibody) and the maternal RSVpreF...
The FDA has approved the first vaccine for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD as a result of respiratory syncytial virus (RSV) in infants, from birth through 6...